Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CO-ALS II colchicine trial in amyotrophic lateral sclerosis
2026-526460-20-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Aug 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in amyotrophic lateral sclerosis (ALS) comparing Colchicine with Placebo (2 arms). Primary endpoint: Monthly decline in ALSFRS-R score. Planned start Aug 2026; status: authorised.
02
Drugs
colchicine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2026-526460-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526460-20-00.